These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37309139)

  • 21. Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out.
    Hickey MD; Wafula E; Ogachi SM; Ojwando H; Orori G; Adede RO; Garraza LG; Petersen ML; Havlir DV; Balzer LB; Ayieko J
    J Acquir Immune Defic Syndr; 2023 Jun; 93(2):154-161. PubMed ID: 36787723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries.
    Romo ML; Esber AL; Owuoth J; Maswai J; Sing'oei V; Iroezindu M; Bahemana E; Kibuuka H; Cavanaugh JS; Shah N; Ake JA; Crowell TA;
    HIV Med; 2023 Oct; 24(10):1066-1074. PubMed ID: 37232057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
    Nelson M; Winston A; Hill A; Mngqibisa R; Bassa A; Orkin C; Rassool M; Rodgers A; Teal V; Kumar S; Teppler H
    AIDS; 2021 Apr; 35(5):759-767. PubMed ID: 33587439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort.
    Bourgi K; Ofner S; Musick B; Wools-Kaloustian K; Humphrey JM; Diero L; Yiannoutsos CT; Gupta SK
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad581. PubMed ID: 38088979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
    Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
    Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    Taramasso L; Berruti M; Briano F; Di Biagio A
    AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
    Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
    Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks.
    Carr M; Richardson R; Tong W; Bloch M; Baker D; Hoy JF;
    AIDS; 2020 Apr; 34(5):789-790. PubMed ID: 31895147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
    Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA;
    Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study.
    Hirigo AT; Yilma D; Astatkie A; Debebe Z
    Ann Med; 2023; 55(2):2242250. PubMed ID: 37531412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
    Cindi Z; Maartens G; Bradford Y; Venter WDF; Sokhela S; Chandiwana NC; Haas DW; Sinxadi P
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):1002-1009. PubMed ID: 33625064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
    Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
    J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.